Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.40 USD
+0.08 (6.06%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.36 -0.04 (-2.86%) 7:04 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCGN 1.40 +0.08(6.06%)
Will OCGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OCGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCGN
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
OCGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends
5 Biotech Breakthrough Stocks to Watch in 2025
Other News for OCGN
Ocugen Faces Merger Termination with Carisma Therapeutics
OCGN makes New 52 Week Closing High on September 17
OCGN forms Jack-in-the-box Bullish on September 16
12 Health Care Stocks Moving In Wednesday's After-Market Session
Is OCGN ready to move higher? Expansion Breakout shows up after rallying 12.15%